CureVac claims delay in German court over alleged infringement of its Covid-19 vaccine by BioNTech a sign in its favor

Katherine Lewin

News Reporter

CureVac is expecting good news in its patent infringement cases for components of its Covid-19 vaccine against Pfizer partner BioNTech in Germany after a court …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CureVac claims delay in German court over alleged infringement of its Covid-19 vaccine by BioNTech a sign in its favor

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Cure­Vac claims de­lay in Ger­man court over al­leged in­fringe­ment of its Covid-19 vac­cine by BioN­Tech a sign in its fa­vor

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

CureVac claims delay in German court over alleged infringement of its Covid-19 vaccine by BioNTech a sign in its favor